Member of the Month: OrthogenRX, Inc

OrthogenRx, Inc. continues to build on its commercial success with the announcement on November 13, 2017 that the FDA approved (P160057) their Class III Medical Device, TriVisc™.  TriVisc™ will compete, along with the Company’s first product, GenVisc® 850, in the $1.1B U.S. market composed of intra-articular injections of hyaluronic acid for the treatment of osteoarthritis knee pain in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics, e.g., acetaminophen.  TriVisc™ directions for use is for three-weekly injections, and will compete in an addressable $450MM market. 

OrthogenRx transformed itself from a start-up to a commercial company in just 2 yrs.  The Company is cash-flow positive in 2016, just 3 years from initial funding, and has a rich pipeline of follow-on products in development.  It is led by a seasoned management team with decades of experience in product development and commercialization.  OrthogenRx’s unique platform and regulatory approval blueprint for its pipeline of products in development and licensing strategies are projected to approach $200MM in revenue by the end of 2020.

Learn more about this PACT member.

Member Spotlight: OrthogenRx, Inc.

OrthogenRx, Inc. a resident of the PA Biotechnology Center in Doylestown has transformed itself from initial Seed funding in January 2014 to commercial launch of its first product in May 2016, GenVisc 850, used in the treatment of osteoarthritis knee pain. In December 2016 the Company reported it was cash-flow positive, and is on track to achieve over $17MM in sales in 2017 in its first full year of sales. The Company is led by an experienced management team with decades of experience in product development, commercialization, sales, marketing, and reimbursement, and now has 20 full-time employees. OrthogenRx was founded by Bucks County resident Michael Daley PhD and was initially funded by a syndicate of Angels and Ben Franklin Technology Partners, including $187,500 in investment from the Venture Capital for Bucks County, VC4BC. OrthogenRx’s unique platform and regulatory approval blueprint afford the company an accelerated go-to-market strategy at a significant reduction in cost and time. The Company also has a rich pipeline of 4 additional products in development which could add up to $200MM in topline revenues by 2021.

Click here to learn more on OrthogenRx, Inc.